We’re developing a non-viral cell and gene therapy delivery platform that leverage STRM MVs to target bone marrow for safe, targeted, and scalable in vivo delivery of next generation therapeutics. Our initial focus is on rare hematological diseases with initial pipeline programs in Fanconi anemia along with in vivo CAR-T therapies.